Tousif all smiles thanks to WFH Humanitarian Aid Program donations

In many countries, patients with hemophilia don’t have access to proper care, and all too often, these patients might not even be able to receive care in a timely fashion when it is available. Tousif, a 16-year old boy from India, suffers severe Factor VIII deficiency.

In September 2016, he fell and developed swelling and pain in a knee joint. Because his parents weren’t aware of the severity of his injury, and because they lacked the financial means to bring him to the hospital, he was not admitted for medical care for several weeks. When he was finally seen by a physician, it was found that Tousif had sustained a supracondylar fracture of the right femur. Because of the delay in treatment, Tousif’s condition had worsened and be had begun to develop septicemia.

In order to receive appropriate care, he was brought to the Karnataka Hemophilia Society (KHS), in Davangere, Karnataka, India where he received surgery and other treatments. During his recovery, Tousif received 66,000 IU of factor thanks to the World Federation of Hemophilia Humanitarian Aid Program. Although it’s disheartening to think of the circumstances that led to the delay in Tousif’s medical care, it’s encouraging to know that donated factor was able to play an integral part in what is expected to be a full recovery.


An increasing number of contributors within the global bleeding disorders community have accepted the challenge of providing a sustainable and predictable supply of donated products. The visionary contribution from Bioverativ and Sobi to the WFH Humanitarian Aid Program translates into 500 million IUs over five years (2015-2020). In addition, the eight-year commitment (2014-2021) from Grifols totaling 200 million IUs, along with a ten-year commitment (2009-2018) from CSL Behring for a total of 22 million IUs, and the three-year agreement (2017-2019) with Green Cross for 6 million IUs, there will now be a more predictable and sustainable flow of humanitarian aid donations to the global community. In addition, the initiatives of Project WISH and Project Recovery allow for the manufacturing of clotting factor concentrates from previously discarded cryopaste which provide treatment products to countries most in need.